Post by SOPHiA GENETICS

🚀 Myriad Genetics and SOPHiA GENETICS partner to develop an innovative #LiquidBiopsy companion diagnostic offering! From the World CB & CDx Summit in Boston, we’re proud to announce a new partnership with Myriad Genetics to bring an innovative, global liquid biopsy companion diagnostic (CDx) test to BioPharma partners. This collaboration combines: 🔹 Myriad’s advanced U.S. laboratory for global clinical trial support 🔹 SOPHiA GENETICS’ decentralized network of 800+ institutions across 70+ countries 💬 “By combining the complementary strengths of a specialty lab leader and a global testing network, we are not only expanding access to innovative oncology testing but also laying the foundation for a new hybrid model in companion diagnostics,” said Jurgi Camblong, Co-founder & CEO, SOPHiA GENETICS “We expect this collaboration with SOPHiA GENETICS to support the development and global commercialization of comprehensive CDx solutions for our BioPharma partners with the potential to positively impact patient lives.” said Sam Raha, President & CEO, Myriad Genetics Together, we’ll initially focus on MSK-ACCESS® powered with SOPHiA DDM™, an innovative liquid biopsy test developed with Memorial Sloan Kettering Cancer Center. This solution will advance personalized oncology testing — from a single blood draw — for patients worldwide. 🔗 Read more about this collaboration: https://lnkd.in/dTWvJyVW Explore MSK-ACCESS® powered with SOPHiA DDM™: https://loom.ly/h9i_3zQ #LiquidBiopsy #PrecisionOncology #CompanionDiagnostics #BioPharma #CancerCare